Literature DB >> 11536039

Overexpression of human O6-alkylguanine DNA alkyltransferase (AGT) prevents MNU induced lymphomas in heterozygous p53 deficient mice.

J S Reese1, E Allay, S L Gerson.   

Abstract

O6-alkylguanine DNA alkyltransferase (AGT) is a key mechanism in the prevention against MNU induced malignant transformation by removal of O6 methyl guanine (O6mG) adducts. We asked whether heterozygous p53 deficient mice (p53+/-) would be more susceptible to MNU induced lymphomas than wild type mice, and whether O6mG adducts were responsible for this susceptibility. To determine whether MGMT overexpression would be protective, p53+/- mice were bred to human MGMT transgenic mice (MGMT+) and treated with 50 mg/kg MNU. MNU increased the incidence of thymic lymphomas in non-transgenic p53+/- mice from 23% (n=13) to 68% (n=22) and decreased the mean latency from 433 to 106 days (P=0.01 compared to untreated mice). Wild type mice had an incidence of 30% (n=38) and a mean latency of 135 days after MNU. Overexpression of MGMT in the thymus of p53+/- mice significantly reduced the lymphoma incidence from 68 to 28% (n=17) and increased the latency from 106 to 167 days (P=0.003). Similarly, the lymphoma incidence in MGMT+/wild type mice decreased from 30 to 8% (n=12) and the latency increased to 297 days (P=0.2). Loss of the wild type allele was found in only 2/17 lymphomas occurring in p53+/- mice and there were no significant point mutations in exons 5-8 of p53. Furthermore, there was no loss of p53 function in these mice. These data demonstrate that unrepaired O6mG lesions act cooperatively with the reduced p53 dose and lead to lymphomagenesis in p53+/- mice, but AGT overexpression and rapid removal of O6mG adducts is protective.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11536039     DOI: 10.1038/sj.onc.1204700

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  The proline rich domain of p53 is dispensable for MGMT-dependent DNA repair and cell survival following alkylation damage.

Authors:  Katherine Baran; Mao Yang; Christopher P Dillon; Leona L Samson; Douglas R Green
Journal:  Cell Death Differ       Date:  2017-07-28       Impact factor: 15.828

2.  Luteinizing hormone receptor deficiency increases the susceptibility to alkylating agent-induced lymphomagenesis in mice.

Authors:  Yinghao Yu; Fangping Yuan; Xian Li; Dexin Lin; Zijian Lan; C V Rao; Zhenmin Lei
Journal:  Horm Cancer       Date:  2010-10       Impact factor: 3.869

Review 3.  Balancing repair and tolerance of DNA damage caused by alkylating agents.

Authors:  Dragony Fu; Jennifer A Calvo; Leona D Samson
Journal:  Nat Rev Cancer       Date:  2012-01-12       Impact factor: 60.716

Review 4.  Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools.

Authors:  Anthony E Pegg
Journal:  Chem Res Toxicol       Date:  2011-04-28       Impact factor: 3.739

Review 5.  Live and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection.

Authors:  Michael D Milsom; David A Williams
Journal:  DNA Repair (Amst)       Date:  2007-05-07

6.  Requirement for phosphorylation of P53 at Ser312 in suppression of chemical carcinogenesis.

Authors:  Elizabeth A Slee; Xin Lu
Journal:  Sci Rep       Date:  2013-10-31       Impact factor: 4.379

7.  MiR-221/222 target the DNA methyltransferase MGMT in glioma cells.

Authors:  Cristina Quintavalle; Davide Mangani; Giuseppina Roscigno; Giulia Romano; Angel Diaz-Lagares; Margherita Iaboni; Elvira Donnarumma; Danilo Fiore; Pasqualino De Marinis; Ylermi Soini; Manel Esteller; Gerolama Condorelli
Journal:  PLoS One       Date:  2013-09-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.